Current Report · Items 2.02, 9.01 · 8-K

Invivyd, Inc.

IVVDNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 13, 2026Accepted Aug 13, 2026, 4:11 PM EDTCIK 1832038Accession 0001193125-26-349193

Company context

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Current securities

IVVDNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02. Results of Operations and Financial Condition. On August 13, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) ivvd-ex99_1.htm

EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is complete; the ongoing study is approaching its planned analysis, and in lieu of a Q2 2026 quarterly earnings call, Invivyd plans to hold an investor call post study completion • LIBERTY study fully dosed with top-line data anticipated in late Q3 2026 • Strong balance sheet with Q2 2026 ending cash and cash equivalents of $160.1 million anticipated to provide runway through DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311 NEW HAVEN, Conn., August 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights. “With our VYD2311 DECLARATION an…

Open exhibit ↗

Get the free weekly BCS email.